Current Perspective on the Natural Compounds and Drug Delivery Techniques in Glioblastoma Multiforme
Abstract
:Simple Summary
Abstract
1. Introduction
2. Underlying Mechanisms for GBM Progress
2.1. The PI3K/AKT/mTOR Signaling
2.2. The Ras Pathway
2.3. The p53 Pathway
2.4. Interleukin-6 (IL-6)/STAT3 Pathway
2.5. Role of Glutamate Receptors in GBM
2.6. Role of Voltage-Gated Ion Channels in GBM
2.7. Oxidative Stress in Glioblastoma Multiforme
2.8. Reactive Oxygen Species and Apoptosis
3. Natural Compounds in GBM
3.1. Quercetin
3.2. Chrysin
3.3. Luteolin
3.4. Genistein
3.5. Catechins
3.6. Resveratrol
3.7. Retinoids
4. Novel Drug Delivery Approaches
4.1. Nanoparticles (NPs)
4.2. Gliadel Wafers
4.3. Drug Delivery in Brain Tissue Using Cellular Carriers
4.4. BBB Transient Disruption for Enhanced Drug Delivery
4.5. Intra Tumoral Injection of Drug-Loaded Vehicles
4.6. Vasculature Targeting via Antibodies
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Acknowledgments
Conflicts of Interest
References
- Weir, H.K.; Thompson, T.D.; Soman, A.; Møller, B.; Leadbetter, S. The past, present, and future of cancer incidence in the United States: 1975 through 2020. Cancer 2015, 121, 1827–1837. [Google Scholar] [CrossRef] [Green Version]
- Hanif, F.; Muzaffar, K.; Perveen, K.; Malhi, S.M.; Simjee, S.U. Glioblastoma multiforme: A review of its epidemiology and pathogenesis through clinical presentation and treatment. Asian Pac. J. Cancer Prev. APJCP 2017, 18, 3. [Google Scholar]
- Ostrom, Q.T.; Gittleman, H.; Fulop, J.; Liu, M.; Blanda, R.; Kromer, C.; Wolinsky, Y.; Kruchko, C.; Barnholtz-Sloan, J.S. CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2008–2012. Neuro-oncology 2015, 17, iv1–iv62. [Google Scholar] [CrossRef]
- Spratt, D.E.; Folkert, M.; Zumsteg, Z.S.; Chan, T.A.; Beal, K.; Gutin, P.H.; Pentsova, E.; Yamada, Y. Temporal relationship of post-operative radiotherapy with temozolomide and oncologic outcome for glioblastoma. J. Neuro-Oncol. 2014, 116, 357–363. [Google Scholar] [CrossRef]
- Ostrom, Q.T.; Gittleman, H.; Farah, P.; Ondracek, A.; Chen, Y.; Wolinsky, Y.; Stroup, N.E.; Kruchko, C.; Barnholtz-Sloan, J.S. CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006–2010. Neuro-oncology 2013, 15 (Suppl. 2), ii1–ii56. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Salazar-Ramiro, A.; Ramírez-Ortega, D.; Pérez de la Cruz, V.; Hérnandez-Pedro, N.Y.; González-Esquivel, D.F.; Sotelo, J.; Pineda, B. Role of redox status in development of glioblastoma. Front. Immunol. 2016, 7, 156. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rinaldi, M.; Caffo, M.; Minutoli, L.; Marini, H.; Abbritti, R.V.; Squadrito, F.; Trichilo, V.; Valenti, A.; Barresi, V.; Altavilla, D. ROS and brain gliomas: An overview of potential and innovative therapeutic strategies. Int. J. Mol. Sci. 2016, 17, 984. [Google Scholar] [CrossRef] [Green Version]
- Tuzgen, S.; Hanimoglu, H.; Tanriverdi, T.; Kacira, T.; Sanus, G.Z.; Atukeren, P.; Dashti, R.; Gumustas, K.; Canbaz, B.; Kaynar, M.Y. Relationship between DNA damage and total antioxidant capacity in patients with glioblastoma multiforme. Clin. Oncol. 2007, 19, 177–181. [Google Scholar] [CrossRef] [PubMed]
- Bhattacharyya, A.; Chattopadhyay, R.; Mitra, S.; Crowe, S.E. Oxidative stress: An essential factor in the pathogenesis of gastrointestinal mucosal diseases. Physiol. Rev. 2014, 94, 329–354. [Google Scholar] [CrossRef] [Green Version]
- Ahmad, F.; Patrick, S.; Sheikh, T.; Sharma, V.; Pathak, P.; Malgulwar, P.B.; Kumar, A.; Joshi, S.D.; Sarkar, C.; Sen, E. Telomerase reverse transcriptase (TERT)-enhancer of zeste homolog 2 (EZH2) network regulates lipid metabolism and DNA damage responses in glioblastoma. J. Neurochem. 2017, 143, 671–683. [Google Scholar] [CrossRef] [Green Version]
- Tudek, B.; Winczura, A.; Janik, J.; Siomek, A.; Foksinski, M.; Oliński, R. Involvement of oxidatively damaged DNA and repair in cancer development and aging. Am. J. Transl. Res. 2010, 2, 254. [Google Scholar]
- Stupp, R.; Hegi, M.E.; Mason, W.P.; Van Den Bent, M.J.; Taphoorn, M.J.B.; Janzer, R.C.; Ludwin, S.K.; Allgeier, A.; Fisher, B.; Belanger, K. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009, 10, 459–466. [Google Scholar] [CrossRef]
- Bao, S.; Wu, Q.; McLendon, R.E.; Hao, Y.; Shi, Q.; Hjelmeland, A.B.; Dewhirst, M.W.; Bigner, D.D.; Rich, J.N. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444, 756–760. [Google Scholar] [CrossRef] [PubMed]
- Louka, M.; Boutou, E.; Bakou, V.; Pappa, V.; Georgoulis, A.; Stürzbecher, H.-W.; Vorgias, C.E.; Vlachodimitropoulos, D. DNA damage response/repair in cancer stem cells—potential vs. controversies. Adv. DNA Repair 2015, 10, 61355. [Google Scholar]
- Panche, A.N.; Diwan, A.D.; Chandra, S.R. Flavonoids: An overview. J. Nutr. Sci. 2016, 5, e47. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Copolovici, D.; Bungau, S.; Boscencu, R.; Tit, D.M.; Copolovici, L. The Fatty Acids Composition and Antioxidant Activity of Walnut Cold Press Oil. Rev. Chim. 2017, 68, 507–509. [Google Scholar] [CrossRef]
- Pallag, A.; Bungau, S.; Tit, D.M.; Jurca, T.; Sirbu, V.; Honiges, A.; Horhogea, C. Comparative Study of Polyphenols, Flavonoids and Chlorophylls in Equisetum arvense L. Populations. Rev. Chim. 2016, 67, 530–533. [Google Scholar]
- Sivasankarapillai, V.S.; Madhu Kumar Nair, R.; Rahdar, A.; Bungau, S.; Zaha, D.C.; Aleya, L.; Tit, D.M. Overview of the anticancer activity of Withaferin A, an active constituent of the Indian Ginseng Withania somnifera. Env. Sci Pollut Res 2020. [Google Scholar] [CrossRef]
- Snyder, R.D.; Gillies, P.J. Reduction of genistein clastogenicity in Chinese hamster V79 cells by daidzein and other flavonoids. Food Chem. Toxicol. 2003, 41, 1291–1298. [Google Scholar] [CrossRef]
- Makkar, R.; Behl, T.; Bungau, S.; Zengin, G.; Mehta, V.; Kumar, A.; Uddin, M.S.; Ashraf, G.M.; Abdel-Daim, M.M.; Arora, S.; et al. Nutraceuticals in Neurological Disorders. Int. J. Molec. Sci. 2020, 21. [Google Scholar] [CrossRef]
- Youdim, K.A.; Shukitt-Hale, B.; Joseph, J.A. Flavonoids and the brain: Interactions at the blood–brain barrier and their physiological effects on the central nervous system. Free Radic. Biol. Med. 2004, 37, 1683–1693. [Google Scholar] [CrossRef]
- Borst, P.; Elferink, R.O. Mammalian ABC transporters in health and disease. Annu. Rev. Biochem. 2002, 71, 537–592. [Google Scholar] [CrossRef] [Green Version]
- Regad, T. Targeting RTK signaling pathways in cancer. Cancers 2015, 7, 1758–1784. [Google Scholar] [CrossRef] [PubMed]
- Hatanpaa, K.J.; Burma, S.; Zhao, D.; Habib, A.A. Epidermal growth factor receptor in glioma: Signal transduction, neuropathology, imaging, and radioresistance. Neoplasia 2010, 12, 675–684. [Google Scholar] [CrossRef] [Green Version]
- Dunn, G.P.; Rinne, M.L.; Wykosky, J.; Genovese, G.; Quayle, S.N.; Dunn, I.F.; Agarwalla, P.K.; Chheda, M.G.; Campos, B.; Wang, A. Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev. 2012, 26, 756–784. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zheng, Y.; McFarland, B.C.; Drygin, D.; Yu, H.; Bellis, S.L.; Kim, H.; Bredel, M.; Benveniste, E.N. Targeting protein kinase CK2 suppresses prosurvival signaling pathways and growth of glioblastoma. Clin. Cancer Res. 2013, 19, 6484–6494. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Fredriksson, L.; Li, H.; Eriksson, U. The PDGF family: Four gene products form five dimeric isoforms. Cytokine Growth Factor Rev. 2004, 15, 197–204. [Google Scholar] [CrossRef] [PubMed]
- Rheinbay, E.; Suvà, M.L.; Gillespie, S.M.; Wakimoto, H.; Patel, A.P.; Shahid, M.; Oksuz, O.; Rabkin, S.D.; Martuza, R.L.; Rivera, M.N. An aberrant transcription factor network essential for Wnt signaling and stem cell maintenance in glioblastoma. Cell Rep. 2013, 3, 1567–1579. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Uhrbom, L.; Hesselager, G.; Nistér, M.; Westermark, B. Induction of brain tumors in mice using a recombinant platelet-derived growth factor B-chain retrovirus. Cancer Res. 1998, 58, 5275–5279. [Google Scholar]
- Westermark, B. Platelet-derived growth factor in glioblastoma—driver or biomarker? Upsala J. Med Sci. 2014, 119, 298–305. [Google Scholar] [CrossRef]
- Verhaak, R.G.W.; Hoadley, K.A.; Purdom, E.; Wang, V.; Qi, Y.; Wilkerson, M.D.; Miller, C.R.; Ding, L.; Golub, T.; Mesirov, J.P. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010, 17, 98–110. [Google Scholar] [CrossRef] [Green Version]
- Brennan, C.W.; Verhaak, R.G.W.; McKenna, A.; Campos, B.; Noushmehr, H.; Salama, S.R.; Zheng, S.; Chakravarty, D.; Sanborn, J.Z.; Berman, S.H. The somatic genomic landscape of glioblastoma. Cell 2013, 155, 462–477. [Google Scholar] [CrossRef]
- Montano, N.; Cenci, T.; Martini, M.; D’Alessandris, Q.G.; Pelacchi, F.; Ricci-Vitiani, L.; Maira, G.; De Maria, R.; Larocca, L.M.; Pallini, R. Expression of EGFRvIII in glioblastoma: Prognostic significance revisited. Neoplasia 2011, 13, 1113–IN1116. [Google Scholar] [CrossRef]
- Hardee, M.E.; Zagzag, D. Mechanisms of glioma-associated neovascularization. Am. J. Pathol. 2012, 181, 1126–1141. [Google Scholar] [CrossRef] [Green Version]
- Holmes, K.; Roberts, O.L.; Thomas, A.M.; Cross, M.J. Vascular endothelial growth factor receptor-2: Structure, function, intracellular signalling and therapeutic inhibition. Cell. Signal. 2007, 19, 2003–2012. [Google Scholar] [CrossRef]
- Kuczynski, E.A.; Patten, S.G.; Coomber, B.L. VEGFR2 expression and TGF-β signaling in initial and recurrent high-grade human glioma. Oncology 2011, 81, 126–134. [Google Scholar] [CrossRef] [PubMed]
- Jaal, J.; Kase, M.; Minajeva, A.; Saretok, M.; Adamson, A.; Junninen, J.; Metsaots, T.; Jõgi, T.; Joonsalu, M.; Vardja, M. VEGFR-2 expression in glioblastoma multiforme depends on inflammatory tumor microenvironment. Int. J. Inflamm. 2015, 2015. [Google Scholar] [CrossRef]
- Riehle, R.D.; Cornea, S.; Degterev, A. Role of phosphatidylinositol 3, 4, 5-trisphosphate in cell signaling. In Lipid-Mediated Protein Signaling; Springer: Berlin/Heidelberg, Germany, 2013; pp. 105–139. [Google Scholar]
- Polivka Jr, J.; Janku, F. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. Pharmacol. Ther. 2014, 142, 164–175. [Google Scholar] [CrossRef]
- Pópulo, H.; Lopes, J.M.; Soares, P. The mTOR signalling pathway in human cancer. Int. J. Mol. Sci. 2012, 13, 1886–1918. [Google Scholar] [CrossRef]
- Gulati, N.; Karsy, M.; Albert, L.; Murali, R.; Jhanwar-Uniyal, M. Involvement of mTORC1 and mTORC2 in regulation of glioblastoma multiforme growth and motility. Int. J. Oncol. 2009, 35, 731–740. [Google Scholar]
- Siddiqui, N.; Sonenberg, N. Signalling to eIF4E in cancer. Biochem. Soc. Trans. 2015, 43, 763–772. [Google Scholar] [CrossRef]
- Li, X.; Gao, T. mTORC 2 phosphorylates protein kinase Cζ to regulate its stability and activity. EMBO Rep. 2014, 15, 191–198. [Google Scholar] [CrossRef] [Green Version]
- Land, S.C.; Tee, A.R. Hypoxia-inducible factor 1α is regulated by the mammalian target of rapamycin (mTOR) via an mTOR signaling motif. J. Biol. Chem. 2007, 282, 20534–20543. [Google Scholar] [CrossRef] [Green Version]
- Dowling, R.J.O.; Topisirovic, I.; Fonseca, B.D.; Sonenberg, N. Dissecting the role of mTOR: Lessons from mTOR inhibitors. Biochim. Biophys. Acta (BBA)-Proteins Proteom. 2010, 1804, 433–439. [Google Scholar] [CrossRef]
- Fan, Q.-W.; Weiss, W.A. Inhibition of PI3K-Akt-mTOR signaling in glioblastoma by mTORC1/2 inhibitors. In mTOR; Springer: Berlin/Heidelberg, Germany, 2012; pp. 349–359. [Google Scholar]
- Fang, X.; Yu, S.X.; Lu, Y.; Bast, R.C.; Woodgett, J.R.; Mills, G.B. Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A. Proc. Natl. Acad. Sci. USA 2000, 97, 11960–11965. [Google Scholar] [CrossRef] [Green Version]
- Li, X.; Wu, C.; Chen, N.; Gu, H.; Yen, A.; Cao, L.; Wang, E.; Wang, L. PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma. Oncotarget 2016, 7, 33440. [Google Scholar] [CrossRef] [Green Version]
- Lu, J.; Getz, G.; Miska, E.A.; Alvarez-Saavedra, E.; Lamb, J.; Peck, D.; Sweet-Cordero, A.; Ebert, B.L.; Mak, R.H.; Ferrando, A.A. MicroRNA expression profiles classify human cancers. Nature 2005, 435, 834–838. [Google Scholar] [CrossRef]
- Hurley, J.B.; Simon, M.I.; Teplow, D.B.; Robishaw, J.D.; Gilman, A.G. Homologies between signal transducing G proteins and ras gene products. Science 1984, 226, 860–862. [Google Scholar] [CrossRef]
- McCubrey, J.A.; Steelman, L.S.; Chappell, W.H.; Abrams, S.L.; Wong, E.W.T.; Chang, F.; Lehmann, B.; Terrian, D.M.; Milella, M.; Tafuri, A. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim. Biophys. Acta (BBA)-Mol. Cell Res. 2007, 1773, 1263–1284. [Google Scholar] [CrossRef] [Green Version]
- Lim, J.-H.; Lee, E.-S.; You, H.-J.; Lee, J.W.; Park, J.-W.; Chun, Y.-S. Ras-dependent induction of HIF-1 α 785 via the Raf/MEK/ERK pathway: A novel mechanism of Ras-mediated tumor promotion. Oncogene 2004, 23, 9427–9431. [Google Scholar] [CrossRef] [Green Version]
- Mao, H.; LeBrun, D.G.; Yang, J.; Zhu, V.F.; Li, M. Deregulated signaling pathways in glioblastoma multiforme: Molecular mechanisms and therapeutic targets. Cancer Investig. 2012, 30, 48–56. [Google Scholar] [CrossRef] [Green Version]
- Rivlin, N.; Brosh, R.; Oren, M.; Rotter, V. Mutations in the p53 tumor suppressor gene: Important milestones at the various steps of tumorigenesis. Genes Cancer 2011, 2, 466–474. [Google Scholar] [CrossRef] [Green Version]
- Ishii, N.; Maier, D.; Merlo, A.; Tada, M.; Sawamura, Y.; Diserens, A.C.; Van Meir, E.G. Frequent Co-Alterations of TP53, p16/CDKN2A, p14ARF, PTEN Tumor Suppressor Genes in Human Glioma Cell Lines. Brain Pathol. 1999, 9, 469–479. [Google Scholar] [CrossRef]
- Tsuchiya, K. Functional restoration of tumor suppressor p53 alters susceptibility of glioblastoma cells to irradiation--analysis using a cell line containing a temperature-sensitive mutant. [Hokkaido Igaku Zasshi] Hokkaido J. Med. Sci. 2000, 75, 265–274. [Google Scholar]
- England, B.; Huang, T.; Karsy, M. Current understanding of the role and targeting of tumor suppressor p53 in glioblastoma multiforme. Tumor Biol. 2013, 34, 2063–2074. [Google Scholar] [CrossRef]
- Haupt, Y.; Maya, R.; Kazaz, A.; Oren, M. Mdm2 promotes the rapid degradation of p53. Nature 1997, 387, 296–299. [Google Scholar] [CrossRef]
- Reifenberger, G.; Ichimura, K.; Reifenberger, J.; Elkahloun, A.G.; Meltzer, P.S.; Collins, V.P. Refined mapping of 12q13–q15 amplicons in human malignant gliomas suggests CDK4/SAS and MDM2 as independent amplification targets. Cancer Res. 1996, 56, 5141–5145. [Google Scholar]
- Riemenschneider, M.J.; Büschges, R.; Wolter, M.; Reifenberger, J.; Boström, J.; Kraus, J.A.; Schlegel, U.; Reifenberger, G. Amplification and overexpression of the MDM4 (MDMX) gene from 1q32 in a subset of malignant gliomas without TP53 mutation or MDM2 amplification. Cancer Res. 1999, 59, 6091–6096. [Google Scholar]
- Crespo, I.; Vital, A.L.; Gonzalez-Tablas, M.; del Carmen Patino, M.; Otero, A.; Lopes, M.C.; de Oliveira, C.; Domingues, P.; Orfao, A.; Tabernero, M.D. Molecular and genomic alterations in glioblastoma multiforme. Am. J. Pathol. 2015, 185, 1820–1833. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hong, D.S.; Angelo, L.S.; Kurzrock, R. Interleukin-6 and its receptor in cancer: Implications for translational therapeutics. Cancer 2007, 110, 1911–1928. [Google Scholar] [CrossRef]
- Aggarwal, V.; Tuli, H.S.; Varol, A.; Thakral, F.; Yerer, M.B.; Sak, K.; Varol, M.; Jain, A.; Khan, M.; Sethi, G. Role of reactive oxygen species in cancer progression: Molecular mechanisms and recent advancements. Biomolecules 2019, 9, 735. [Google Scholar] [CrossRef] [Green Version]
- Goswami, S.; Gupta, A.; Sharma, S.K. Interleukin-6-mediated autocrine growth promotion in human glioblastoma multiforme cell line U87MG. J. Neurochem. 1998, 71, 1837–1845. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yeung, Y.T.; McDonald, K.L.; Grewal, T.; Munoz, L. Interleukins in glioblastoma pathophysiology: Implications for therapy. Br. J. Pharm. 2013, 168, 591–606. [Google Scholar] [CrossRef] [Green Version]
- Ashizawa, T.; Miyata, H.; Iizuka, A.; Komiyama, M.; Oshita, C.; Kume, A.; Nogami, M.; Yagoto, M.; Ito, I.; Oishi, T.; et al. Effect of the STAT3 inhibitor STX-0119 on the proliferation of cancer stem-like cells derived from recurrent glioblastoma. Int. J. Oncol. 2013, 43, 219–227. [Google Scholar] [CrossRef] [Green Version]
- Li, R.; Li, G.; Deng, L.; Liu, Q.; Dai, J.; Shen, J.; Zhang, J. IL-6 augments the invasiveness of U87MG human glioblastoma multiforme cells via up-regulation of MMP-2 and fascin-1. Oncol. Rep. 2010, 23, 1553–1559. [Google Scholar] [CrossRef] [Green Version]
- Anton, K.; Banerjee, D.; Glod, J. Macrophage-associated mesenchymal stem cells assume an activated, migratory, pro-inflammatory phenotype with increased IL-6 and CXCL10 secretion. PLoS ONE 2012, 7, e35036. [Google Scholar] [CrossRef] [Green Version]
- Carmeliet, P. Angiogenesis in life, disease and medicine. Nature 2005, 438, 932–936. [Google Scholar] [CrossRef] [PubMed]
- Majumdar, A.; Ahmad, F.; Sheikh, T.; Bhagat, R.; Pathak, P.; Joshi, S.D.; Seth, P.; Tandon, V.; Tripathi, M.; Saratchandra, P. miR-217–casein kinase-2 cross talk regulates ERK activation in ganglioglioma. J. Mol. Med. 2017, 95, 1215–1226. [Google Scholar] [CrossRef] [PubMed]
- Yool, A.J.; Ramesh, S.A. Molecular targets for combined therapeutic strategies to limit glioblastoma cell migration and invasion. Front. Pharmacol. 2020, 11, 358. [Google Scholar] [CrossRef] [Green Version]
- Dingledine, R.; Borges, K.; Bowie, D.; Traynelis, S.F. The glutamate receptor ion channels. Pharmacol. Rev. 1999, 51, 7–62. [Google Scholar]
- Maas, S.; Patt, S.; Schrey, M.; Rich, A. Underediting of glutamate receptor GluR-B mRNA in malignant gliomas. Proc. Natl. Acad. Sci. USA 2001, 98, 14687–14692. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kuzma-Kozakiewicz, M.; Andersen, P.M.; Ciecwierska, K.; Vázquez, C.; Helczyk, O.; Loose, M.; Uttner, I.; Ludolph, A.C.; Lulé, D. An observational study on quality of life and preferences to sustain life in locked-in state. Neurology 2019, 93, e938–e945. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Shin, J.H.; Park, K.W.; Heo, K.O.; Chung, S.J.; Choo, M.-S. Urodynamic study for distinguishing multiple system atrophy from Parkinson disease. Neurology 2019, 93, e946–e953. [Google Scholar] [CrossRef] [PubMed]
- Malacrida, A.; Rivara, M.; Di Domizio, A.; Cislaghi, G.; Miloso, M.; Zuliani, V.; Nicolini, G. 3D proteome-wide scale screening and activity evaluation of a new ALKBH5 inhibitor in U87 glioblastoma cell line. Bioorganic Med. Chem. 2020, 28, 115300. [Google Scholar] [CrossRef]
- Schieber, M.; Chandel, N.S. ROS function in redox signaling and oxidative stress. Curr. Biol. 2014, 24, R453–R462. [Google Scholar] [CrossRef] [Green Version]
- Trachootham, D.; Alexandre, J.; Huang, P. Targeting cancer cells by ROS-mediated mechanisms: A radical therapeutic approach? Nat. Rev. Drug Discov. 2009, 8, 579–591. [Google Scholar] [CrossRef]
- Spitz, D.R.; Sim, J.E.; Ridnour, L.A.; Galoforo, S.S.; Lee, Y.J. Glucose deprivation-induced oxidative stress in human tumor cells: A fundamental defect in metabolism? Ann. N. Y. Acad. Sci. 2000, 899, 349–362. [Google Scholar] [CrossRef]
- Vaughn, A.E.; Deshmukh, M. Glucose metabolism inhibits apoptosis in neurons and cancer cells by redox inactivation of cytochrome c. Nat. Cell Biol. 2008, 10, 1477–1483. [Google Scholar] [CrossRef]
- Oberley, L.W.; Oberley, T.D.; Buettner, G.R. Cell division in normal and transformed cells: The possible role of superoxide and hydrogen peroxide. Med. Hypotheses 1981, 7, 21–42. [Google Scholar] [CrossRef] [Green Version]
- Bellissimo, M.I.; Amado, D.; Abdalla, D.S.P.; Ferreira, E.C.; Cavalheiro, E.A.; da Graça Naffah-Mazzacoratti, M. Superoxide dismutase, glutathione peroxidase activities and the hydroperoxide concentration are modified in the hippocampus of epileptic rats. Epilepsy Res. 2001, 46, 121–128. [Google Scholar] [CrossRef]
- Rao, G.M.; Rao, A.V.; Raja, A.; Rao, S.; Rao, A. Role of antioxidant enzymes in brain tumours. Clin. Chim. Acta 2000, 296, 203–212. [Google Scholar] [CrossRef]
- Houée-Lévin, C.; Bobrowski, K.; Horakova, L.; Karademir, B.; Schöneich, C.; Davies, M.J.; Spickett, C.M. Exploring oxidative modifications of tyrosine: An update on mechanisms of formation, advances in analysis and biological consequences. Free Radic. Res. 2015, 49, 347–373. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Meng, T.-C.; Fukada, T.; Tonks, N.K. Reversible oxidation and inactivation of protein tyrosine phosphatases in vivo. Mol. Cell 2002, 9, 387–399. [Google Scholar] [CrossRef]
- Esposito, F.; Chirico, G.; Gesualdi, N.M.; Posadas, I.; Ammendola, R.; Russo, T.; Cirino, G.; Cimino, F. Protein kinase B activation by reactive oxygen species is independent of tyrosine kinase receptor phosphorylation and requires SRC activity. J. Biol. Chem. 2003, 278, 20828–20834. [Google Scholar] [CrossRef] [Green Version]
- Kwon, J.; Lee, S.-R.; Yang, K.-S.; Ahn, Y.; Kim, Y.J.; Stadtman, E.R.; Rhee, S.G. Reversible oxidation and inactivation of the tumor suppressor PTEN in cells stimulated with peptide growth factors. Proc. Natl. Acad. Sci. USA 2004, 101, 16419–16424. [Google Scholar] [CrossRef] [Green Version]
- Latimer, H.R.; Veal, E.A. Peroxiredoxins in regulation of MAPK signalling pathways; sensors and barriers to signal transduction. Mol. Cells 2016, 39, 40. [Google Scholar] [PubMed] [Green Version]
- Hayes, J.D.; Dinkova-Kostova, A.T. The Nrf2 regulatory network provides an interface between redox and intermediary metabolism. Trends Biochem. Sci. 2014, 39, 199–218. [Google Scholar] [CrossRef]
- Dreger, H.; Westphal, K.; Weller, A.; Baumann, G.; Stangl, V.; Meiners, S.; Stangl, K. Nrf2-dependent upregulation of antioxidative enzymes: A novel pathway for proteasome inhibitor-mediated cardioprotection. Cardiovasc. Res. 2009, 83, 354–361. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Anderson, D.C.; Asinger, R.W.; Newburg, S.M.; Farmer, C.C.; Wang, K.; Bundlie, S.R.; Koller, R.L.; Jagiella, W.M.; Kreher, S.; Jorgensen, C.R. Design of a multicenter randomized trial for the Stroke Prevention in Atrial Fibrillation Study. Stroke 1990, 21, 538–545. [Google Scholar]
- Ahmad, F.; Dixit, D.; Sharma, V.; Kumar, A.; Joshi, S.D.; Sarkar, C.; Sen, E. Nrf2-driven TERT regulates pentose phosphate pathway in glioblastoma. Cell Death Dis. 2016, 7, e2213. [Google Scholar] [CrossRef] [Green Version]
- Ahmad, F.; Sun, Q.; Patel, D.; Stommel, J.M. Cholesterol metabolism: A potential therapeutic target in glioblastoma. Cancers 2019, 11, 146. [Google Scholar] [CrossRef] [Green Version]
- Wei, Y.; Jiang, Y.; Zou, F.; Liu, Y.; Wang, S.; Xu, N.; Xu, W.; Cui, C.; Xing, Y.; Liu, Y. Activation of PI3K/Akt pathway by CD133-p85 interaction promotes tumorigenic capacity of glioma stem cells. Proc. Natl. Acad. Sci. USA 2013, 110, 6829–6834. [Google Scholar] [CrossRef] [Green Version]
- Godoy, P.R.D.V.; Pour Khavari, A.; Rizzo, M.; Sakamoto-Hojo, E.T.; Haghdoost, S. Targeting NRF2, regulator of antioxidant system, to sensitize glioblastoma neurosphere cells to radiation-induced oxidative stress. Oxidative Med. Cell. Longev. 2020, 2020. [Google Scholar] [CrossRef]
- Jia, Y.; Wang, H.; Wang, Q.; Ding, H.; Wu, H.; Pan, H. Silencing Nrf2 impairs glioma cell proliferation via AMPK-activated mTOR inhibition. Biochem. Biophys. Res. Commun. 2016, 469, 665–671. [Google Scholar] [CrossRef]
- No, J.H.; Kim, Y.-B.; Song, Y.S. Targeting nrf2 signaling to combat chemoresistance. J. Cancer Prev. 2014, 19, 111. [Google Scholar] [CrossRef]
- Melnik, B.C. p53: Key conductor of all anti-acne therapies. J. Transl. Med. 2017, 15, 1–12. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Vickers, N.J. Animal communication: When i’m calling you, will you answer too? Curr. Biol. 2017, 27, R713–R715. [Google Scholar] [CrossRef]
- Pinnix, Z.K.; Miller, L.D.; Wang, W.; D’Agostino, R.; Kute, T.; Willingham, M.C.; Hatcher, H.; Tesfay, L.; Sui, G.; Di, X. Ferroportin and iron regulation in breast cancer progression and prognosis. Sci. Transl. Med. 2010, 2, 43ra56. [Google Scholar] [CrossRef] [PubMed]
- Wang, G.; Wang, J.; Zhao, H.; Wang, J.; To, S.S.T. The role of Myc and let-7a in glioblastoma, glucose metabolism and response to therapy. Arch. Biochem. Biophys. 2015, 580, 84–92. [Google Scholar] [CrossRef] [PubMed]
- Özcan, E.; Çakır, T. Reconstructed metabolic network models predict flux-level metabolic reprogramming in glioblastoma. Front. Neurosci. 2016, 10, 156. [Google Scholar] [CrossRef] [Green Version]
- Wu, J.; Liu, Y.; Cho, K.; Dong, X.; Teng, L.; Han, D.; Liu, H.; Chen, X.; Chen, X.; Hou, X. Downregulation of TRAP1 sensitizes glioblastoma cells to temozolomide chemotherapy through regulating metabolic reprogramming. Neuroreport 2016, 27, 136–144. [Google Scholar] [CrossRef] [PubMed]
- Yuen, C.A.; Asuthkar, S.; Guda, M.R.; Tsung, A.J.; Velpula, K.K. Cancer stem cell molecular reprogramming of the Warburg effect in glioblastomas: A new target gleaned from an old concept. CNS Oncol. 2016, 5, 101–108. [Google Scholar] [CrossRef]
- Jiang, W.; Finniss, S.; Cazacu, S.; Xiang, C.; Brodie, Z.; Mikkelsen, T.; Poisson, L.; Shackelford, D.B.; Brodie, C. Repurposing phenformin for the targeting of glioma stem cells and the treatment of glioblastoma. Oncotarget 2016, 7, 56456. [Google Scholar] [CrossRef] [Green Version]
- Ahmad, F.; Ghosh, S.; Sinha, S.; Joshi, S.D.; Mehta, V.S.; Sen, E. TGF-β-induced hCG-β regulates redox homeostasis in glioma cells. Mol. Cell. Biochem. 2015, 399, 105–112. [Google Scholar] [CrossRef] [PubMed]
- Shen, H.; Hau, E.; Joshi, S.; Dilda, P.J.; McDonald, K.L. Sensitization of glioblastoma cells to irradiation by modulating the glucose metabolism. Mol. Cancer Ther. 2015, 14, 1794–1804. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yang, W.; Wei, J.; Guo, T.; Shen, Y.; Liu, F. Knockdown of miR-210 decreases hypoxic glioma stem cells stemness and radioresistance. Exp. Cell Res. 2014, 326, 22–35. [Google Scholar] [CrossRef]
- Nie, Q.; Guo, P.; Guo, L.; Lan, J.; Lin, Y.; Guo, F.; Zhou, S.; Ge, J.; Mao, Q.; Li, X. Overexpression of isocitrate dehydrogenase-1R132H enhances the proliferation of A172 glioma cells via aerobic glycolysis. Mol. Med. Rep. 2015, 11, 3715–3721. [Google Scholar] [CrossRef] [Green Version]
- Velpula, K.K.; Bhasin, A.; Asuthkar, S.; Tsung, A.J. Combined targeting of PDK1 and EGFR triggers regression of glioblastoma by reversing the Warburg effect. Cancer Res. 2013, 73, 7277–7289. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chandra, J.; Samali, A.; Orrenius, S. Triggering and modulation of apoptosis by oxidative stress. Free Radic. Biol. Med. 2000, 29, 323–333. [Google Scholar] [CrossRef]
- Wang, L.; Azad, N.; Kongkaneramit, L.; Chen, F.; Lu, Y.; Jiang, B.-H.; Rojanasakul, Y. The Fas death signaling pathway connecting reactive oxygen species generation and FLICE inhibitory protein down-regulation. J. Immunol. 2008, 180, 3072–3080. [Google Scholar] [CrossRef] [Green Version]
- Stennicke, H.R.; Deveraux, Q.L.; Humke, E.W.; Reed, J.C.; Dixit, V.M.; Salvesen, G.S. Caspase-9 can be activated without proteolytic processing. J. Biol. Chem. 1999, 274, 8359–8362. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Madesh, M.; Hajnóczky, G.r. VDAC-dependent permeabilization of the outer mitochondrial membrane by superoxide induces rapid and massive cytochrome c release. J. Cell Biol. 2001, 155, 1003–1016. [Google Scholar] [CrossRef] [Green Version]
- Luanpitpong, S.; Chanvorachote, P.; Stehlik, C.; Tse, W.; Callery, P.S.; Wang, L.; Rojanasakul, Y. Regulation of apoptosis by Bcl-2 cysteine oxidation in human lung epithelial cells. Mol. Biol. Cell 2013, 24, 858–869. [Google Scholar] [CrossRef] [PubMed]
- Scherz-Shouval, R.; Elazar, Z. Regulation of autophagy by ROS: Physiology and pathology. Trends Biochem. Sci. 2011, 36, 30–38. [Google Scholar] [CrossRef] [PubMed]
- Poillet-Perez, L.; Despouy, G.; Delage-Mourroux, R.; Boyer-Guittaut, M. Interplay between ROS and autophagy in cancer cells, from tumor initiation to cancer therapy. Redox Biol. 2015, 4, 184–192. [Google Scholar] [CrossRef] [Green Version]
- Dom, M.; Offner, F.; Vanden Berghe, W.; Van Ostade, X. Proteomic characterization of Withaferin A-targeted protein networks for the treatment of monoclonal myeloma gammopathies. J. Proteom. 2018, 179, 17–29. [Google Scholar] [CrossRef] [PubMed]
- Li, L.; Ishdorj, G.; Gibson, S.B. Reactive oxygen species regulation of autophagy in cancer: Implications for cancer treatment. Free Radic. Biol. Med. 2012, 53, 1399–1410. [Google Scholar] [CrossRef] [PubMed]
- De Raedt, T.; Walton, Z.; Yecies, J.L.; Li, D.; Chen, Y.; Malone, C.F.; Maertens, O.; Jeong, S.M.; Bronson, R.T.; Lebleu, V. Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors. Cancer Cell 2011, 20, 400–413. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Galluzzi, L.; Kroemer, G. Necroptosis: A specialized pathway of programmed necrosis. Cell 2008, 135, 1161–1163. [Google Scholar] [CrossRef] [Green Version]
- Kim, Y.-S.; Morgan, M.J.; Choksi, S.; Liu, Z.-G. TNF-induced activation of the Nox1 NADPH oxidase and its role in the induction of necrotic cell death. Mol. Cell 2007, 26, 675–687. [Google Scholar] [CrossRef]
- Jiang, L.; Kon, N.; Li, T.; Wang, S.-J.; Su, T.; Hibshoosh, H.; Baer, R.; Gu, W. Ferroptosis as a p53-mediated activity during tumour suppression. Nature 2015, 520, 57–62. [Google Scholar] [CrossRef] [Green Version]
- Bernstein, J.J.; Woodard, C.A. Glioblastoma cells do not intravasate into blood vessels. Neurosurgery 1995, 36, 124–132. [Google Scholar] [CrossRef]
- Silbergeld, D.L.; Rostomily, R.C.; Alvord, E.C. The cause of death in patients with glioblastoma is multifactorial. J. Neuro-Oncol. 1991, 10, 179–185. [Google Scholar] [CrossRef] [PubMed]
- Rajaraman, P.; Hutchinson, A.; Rothman, N.; Black, P.M.; Fine, H.A.; Loeffler, J.S.; Selker, R.G.; Shapiro, W.R.; Linet, M.S.; Inskip, P.D. Oxidative response gene polymorphisms and risk of adult brain tumors. Neuro-Oncolgy 2008, 10, 709–715. [Google Scholar] [CrossRef] [Green Version]
- Gupta, S.; Afaq, F.; Mukhtar, H. Selective growth-inhibitory, cell-cycle deregulatory and apoptotic response of apigenin in normal versus human prostate carcinoma cells. Biochem. Biophys. Res. Commun. 2001, 287, 914–920. [Google Scholar] [CrossRef] [PubMed]
- Sak, K. Cytotoxicity of dietary flavonoids on different human cancer types. Pharmacogn. Rev. 2014, 8, 122. [Google Scholar] [CrossRef] [Green Version]
- Atiq, A.; Parhar, I. Anti-neoplastic Potential of Flavonoids and Polysaccharide Phytochemicals in Glioblastoma. Molecules 2020, 25. [Google Scholar] [CrossRef]
- Jakubowicz-Gil, J.; Langner, E.; Bądziul, D.; Wertel, I.; Rzeski, W. Apoptosis induction in human glioblastoma multiforme T98G cells upon temozolomide and quercetin treatment. Tumor Biol. 2013, 34, 2367–2378. [Google Scholar] [CrossRef] [Green Version]
- Braganhol, E.; Zamin, L.L.; Canedo, A.D.; Horn, F.; Tamajusuku, A.S.K.; Wink, M.R.; Salbego, C.; Battastini, A.M.O. Antiproliferative effect of quercetin in the human U138MG glioma cell line. Anti-Cancer Drugs 2006, 17, 663–671. [Google Scholar] [CrossRef]
- Siegelin, M.D.; Reuss, D.E.; Habel, A.; Rami, A.; Von Deimling, A. Quercetin promotes degradation of survivin and thereby enhances death-receptor–mediated apoptosis in glioma cells. Neuro-oncology 2009, 11, 122–131. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kim, E.J.; Choi, C.H.; Park, J.Y.; Kang, S.K.; Kim, Y.K. Underlying mechanism of quercetin-induced cell death in human glioma cells. Neurochem. Res. 2008, 33, 971–979. [Google Scholar] [CrossRef]
- Mathews, T.P.; Hill, S.; Rose, K.L.; Ivanova, P.T.; Lindsley, C.W.; Brown, H.A. Human phospholipase D activity transiently regulates pyrimidine biosynthesis in malignant gliomas. ACS Chem. Biol. 2015, 10, 1258–1268. [Google Scholar] [CrossRef]
- Park, M.H. Quercetin-induced downregulation of phospholipase D1 inhibits proliferation and invasion in U87 glioma cells. Biochem. Biophys. Res. Commun. 2011, 412, 710–715. [Google Scholar] [CrossRef]
- Chatterjee, S.; Burns, T.F. Targeting heat shock proteins in cancer: A promising therapeutic approach. Int. J. Mol. Sci. 2017, 18, 1978. [Google Scholar] [CrossRef] [Green Version]
- Ciocca, D.R.; Rozados, V.R.; Carrión, F.D.C.; Gervasoni, S.I.; Matar, P.; Scharovsky, O.G. Hsp25 and Hsp70 in rodent tumors treated with doxorubicin and lovastatin. Cell Stress Chaperones 2003, 8, 26. [Google Scholar] [CrossRef] [Green Version]
- Assimakopoulou, M. Human meningiomas: Immunohistochemical localization of progesterone receptor and heat shock protein 27 and absence of estrogen receptor and PS2. Cancer Detect. Prev. 2000, 24, 163–168. [Google Scholar] [PubMed]
- Yu, Z.; Zhi, J.; Peng, X.; Zhong, X.; Xu, A. Clinical significance of HSP27 expression in colorectal cancer. Mol. Med. Rep. 2010, 3, 953–958. [Google Scholar] [CrossRef] [PubMed]
- Hsu, H.S.; Lin, J.H.; Huang, W.C.; Hsu, T.W.; Su, K.; Chiou, S.H.; Tsai, Y.T.; Hung, S.C. Chemoresistance of lung cancer stemlike cells depends on activation of Hsp27. Cancer 2011, 117, 1516–1528. [Google Scholar] [CrossRef] [PubMed]
- Michaud-Levesque, J.; Bousquet-Gagnon, N.; Béliveau, R. Quercetin abrogates IL-6/STAT3 signaling and inhibits glioblastoma cell line growth and migration. Exp. Cell Res. 2012, 318, 925–935. [Google Scholar] [CrossRef]
- Naz, S.; Imran, M.; Rauf, A.; Orhan, I.E.; Shariati, M.A.; Iahtisham Ul, H.; IqraYasmin; Shahbaz, M.; Qaisrani, T.B.; Shah, Z.A. Chrysin: Pharmacological and therapeutic properties. Life Sci. 2019, 235, 116797. [Google Scholar] [CrossRef]
- Sun, L.R.; Zhou, W.; Zhang, H.M.; Guo, Q.S.; Yang, W.; Li, B.J.; Sun, Z.H.; Gao, S.H.; Cui, R.J. Modulation of Multiple Signaling Pathways of the Plant-Derived Natural Products in Cancer. Front. Oncol. 2019, 9, 1153. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Weng, M.-S.; Ho, Y.-S.; Lin, J.-K. Chrysin induces G1 phase cell cycle arrest in C6 glioma cells through inducing p21Waf1/Cip1 expression: Involvement of p38 mitogen-activated protein kinase. Biochem. Pharmacol. 2005, 69, 1815–1827. [Google Scholar] [CrossRef]
- Wang, J.; Wang, H.; Sun, K.; Wang, X.; Pan, H.; Zhu, J.; Ji, X.; Li, X. Chrysin suppresses proliferation, migration, and invasion in glioblastoma cell lines via mediating the ERK/Nrf2 signaling pathway. Drug Des. Dev. Ther. 2018, 12, 721. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Souza, L.C.; Antunes, M.S.; Filho, C.B.; Del Fabbro, L.; de Gomes, M.G.; Goes, A.T.; Donato, F.; Prigol, M.; Boeira, S.P.; Jesse, C.R. Flavonoid Chrysin prevents age-related cognitive decline via attenuation of oxidative stress and modulation of BDNF levels in aged mouse brain. Pharm. Biochem Behav. 2015, 134, 22–30. [Google Scholar] [CrossRef] [PubMed]
- Liao, C.L.; Chen, C.M.; Chang, Y.Z.; Liu, G.Y.; Hung, H.C.; Hsieh, T.Y.; Lin, C.L. Pine (Pinus morrisonicola Hayata) needle extracts sensitize GBM8901 human glioblastoma cells to temozolomide by downregulating autophagy and O(6)-methylguanine-DNA methyltransferase expression. J. Agric Food Chem. 2014, 62, 10458–10467. [Google Scholar] [CrossRef] [PubMed]
- Gao, A.M.; Ke, Z.P.; Shi, F.; Sun, G.C.; Chen, H. Chrysin enhances sensitivity of BEL-7402/ADM cells to doxorubicin by suppressing PI3K/Akt/Nrf2 and ERK/Nrf2 pathway. Chem. Biol. Interact. 2013, 206, 100–108. [Google Scholar] [CrossRef]
- Khoo, B.Y.; Chua, S.L.; Balaram, P. Apoptotic effects of chrysin in human cancer cell lines. Int. J. Mol. Sci. 2010, 11, 2188–2199. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mani, R.; Natesan, V. Chrysin: Sources, beneficial pharmacological activities, and molecular mechanism of action. Phytochemistry 2018, 145, 187–196. [Google Scholar] [CrossRef]
- Eatemadi, A.; Daraee, H.; Aiyelabegan, H.T.; Negahdari, B.; Rajeian, B.; Zarghami, N. Synthesis and Characterization of Chrysin-loaded PCL-PEG-PCL nanoparticle and its effect on breast cancer cell line. Biomed. Pharm. 2016, 84, 1915–1922. [Google Scholar] [CrossRef]
- Chen, Z.; Kong, S.; Song, F.; Li, L.; Jiang, H. Pharmacokinetic study of luteolin, apigenin, chrysoeriol and diosmetin after oral administration of Flos Chrysanthemi extract in rats. Fitoterapia 2012, 83, 1616–1622. [Google Scholar] [CrossRef]
- Wang, Q.; Wang, H.; Jia, Y.; Pan, H.; Ding, H. Luteolin induces apoptosis by ROS/ER stress and mitochondrial dysfunction in gliomablastoma. Cancer Chemother. Pharm. 2017, 79, 1031–1041. [Google Scholar] [CrossRef] [PubMed]
- Chakrabarti, M.; Ray, S.K. Anti-tumor activities of luteolin and silibinin in glioblastoma cells: Overexpression of miR-7–1-3p augmented luteolin and silibinin to inhibit autophagy and induce apoptosis in glioblastoma in vivo. Apoptosis 2016, 21, 312–328. [Google Scholar] [CrossRef] [PubMed]
- Anson, D.M.; Wilcox, R.M.; Huseman, E.D.; Stump, T.A.; Paris, R.L.; Darkwah, B.O.; Lin, S.; Adegoke, A.O.; Gryka, R.J.; Jean-Louis, D.S.; et al. Luteolin Decreases Epidermal Growth Factor Receptor-Mediated Cell Proliferation and Induces Apoptosis in Glioblastoma Cell Lines. Basic Clin Pharm. Toxicol. 2018, 123, 678–686. [Google Scholar] [CrossRef]
- Tsui, K.H.; Chung, L.C.; Feng, T.H.; Chang, P.L.; Juang, H.H. Upregulation of prostate-derived Ets factor by luteolin causes inhibition of cell proliferation and cell invasion in prostate carcinoma cells. Int. J. Cancer 2012, 130, 2812–2823. [Google Scholar] [CrossRef] [PubMed]
- Markaverich, B.M.; Vijjeswarapu, M.; Shoulars, K.; Rodriguez, M. Luteolin and gefitinib regulation of EGF signaling pathway and cell cycle pathway genes in PC-3 human prostate cancer cells. J. Steroid Biochem. Mol. Biol. 2010, 122, 219–231. [Google Scholar] [CrossRef] [Green Version]
- Zhou, Q.; Yan, B.; Hu, X.; Li, X.-B.; Zhang, J.; Fang, J. Luteolin inhibits invasion of prostate cancer PC3 cells through E-cadherin. Mol. Cancer Ther. 2009, 8, 1684–1691. [Google Scholar] [CrossRef] [Green Version]
- You, Y.; Wang, R.; Shao, N.; Zhi, F.; Yang, Y. Luteolin suppresses tumor proliferation through inducing apoptosis and autophagy via MAPK activation in glioma. Onco Targets Therapy 2019, 12, 2383. [Google Scholar] [CrossRef] [Green Version]
- Kikuta, S. The Cytotoxic Effect of Genistein, a Soybean Isoflavone, against Cultured Tribolium Cells. Insects 2020, 11, 241. [Google Scholar] [CrossRef]
- Ahmad, I.U.; Forman, J.D.; Sarkar, F.H.; Hillman, G.G.; Heath, E.; Vaishampayan, U.; Cher, M.L.; Andic, F.; Rossi, P.J.; Kucuk, O. Soy isoflavones in conjunction with radiation therapy in patients with prostate cancer. Nutr. Cancer 2010, 62, 996–1000. [Google Scholar] [CrossRef] [Green Version]
- Surh, Y.-J. Cancer chemoprevention with dietary phytochemicals. Nat. Rev. Cancer 2003, 3, 768–780. [Google Scholar] [CrossRef]
- Kikuchi, H.; Yuan, B.; Hu, X.; Okazaki, M. Chemopreventive and anticancer activity of flavonoids and its possibility for clinical use by combining with conventional chemotherapeutic agents. Am. J. Cancer Res. 2019, 9, 1517. [Google Scholar] [PubMed]
- Puli, S.; Jain, A.; Lai, J.C.K.; Bhushan, A. Effect of combination treatment of rapamycin and isoflavones on mTOR pathway in human glioblastoma (U87) cells. Neurochem. Res. 2010, 35, 986–993. [Google Scholar] [CrossRef] [PubMed]
- Khoshyomn, S.; Nathan, D.; Manske, G.C.; Osler, T.M.; Penar, P.L. Synergistic effect of genistein and BCNU on growth inhibition and cytotoxicity of glioblastoma cells. J. Neurooncol. 2002, 57, 193–200. [Google Scholar] [CrossRef] [PubMed]
- Ravindranath, M.H.; Muthugounder, S.; Presser, N.; Viswanathan, S. Anticancer therapeutic potential of soy isoflavone, genistein. Complementary Altern. Approaches Biomed. 2004, 121–165. [Google Scholar]
- Schmidt, F.; Knobbe, C.B.; Frank, B.; Wolburg, H.; Weller, M. The topoisomerase II inhibitor, genistein, induces G2/M arrest and apoptosis in human malignant glioma cell lines. Oncol. Rep. 2008, 19, 1061–1066. [Google Scholar] [CrossRef] [Green Version]
- Khaw, A.K.; Yong, J.W.; Kalthur, G.; Hande, M.P. Genistein induces growth arrest and suppresses telomerase activity in brain tumor cells. Genes Chromosomes Cancer 2012, 51, 961–974. [Google Scholar] [CrossRef]
- Pavese, J.M.; Farmer, R.L.; Bergan, R.C. Inhibition of cancer cell invasion and metastasis by genistein. Cancer Metastasis Rev. 2010, 29, 465–482. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Poncet-Legrand, C.; Gautier, C.; Cheynier, V.; Imberty, A. Interactions between Flavan-3-ols and Poly(l-proline) Studied by Isothermal Titration Calorimetry: Effect of the Tannin Structure. J. Agric. Food Chem. 2007, 55, 9235–9240. [Google Scholar] [CrossRef]
- Auger, C.; Al-Awwadi, N.; Bornet, A.; Rouanet, J.-M.; Gasc, F.; Cros, G.; Teissedre, P.-L. Catechins and procyanidins in Mediterranean diets. Food Res. Int. 2004, 37, 233–245. [Google Scholar] [CrossRef]
- Zhu, M.; Chen, Y.; Li, R.C. Oral absorption and bioavailability of tea catechins. Planta Med. 2000, 66, 444–447. [Google Scholar] [CrossRef] [PubMed]
- Vaidyanathan, J.B.; Walle, T. Cellular uptake and efflux of the tea flavonoid (-) epicatechin-3-gallate in the human intestinal cell line Caco-2. J. Pharmacol. Exp. Ther. 2003, 307, 745–752. [Google Scholar] [CrossRef]
- Faria, A.; Pestana, D.; Teixeira, D.; Couraud, P.O.; Romero, I.; Weksler, B.; de Freitas, V.; Mateus, N.; Calhau, C. Insights into the putative catechin and epicatechin transport across blood-brain barrier. Food Funct 2011, 2, 39–44. [Google Scholar] [CrossRef] [PubMed]
- Spencer, J.P. Flavonoids and brain health: Multiple effects underpinned by common mechanisms. Genes Nutr. 2009, 4, 243–250. [Google Scholar] [CrossRef] [Green Version]
- Spencer, J.P. The interactions of flavonoids within neuronal signalling pathways. Genes Nutr. 2007, 2, 257–273. [Google Scholar] [CrossRef] [Green Version]
- Park, I.J.; Lee, Y.K.; Hwang, J.T.; Kwon, D.Y.; Ha, J.; Park, O.J. Green tea catechin controls apoptosis in colon cancer cells by attenuation of H2O2-stimulated COX-2 expression via the AMPK signaling pathway at low-dose H2O2. Ann. N. Y. Acad. Sci. 2009, 1171, 538–544. [Google Scholar] [CrossRef]
- Das, A.; Banik, N.L.; Ray, S.K. Flavonoids activated caspases for apoptosis in human glioblastoma T98G and U87MG cells but not in human normal astrocytes. Cancer 2010, 116, 164–176. [Google Scholar] [CrossRef] [Green Version]
- Berman, A.Y.; Motechin, R.A.; Wiesenfeld, M.Y.; Holz, M.K. The therapeutic potential of resveratrol: A review of clinical trials. NPJ Precis. Oncol. 2017, 1, 1–9. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kiskova, T.; Kubatka, P.; Büsselberg, D.; Kassayova, M. The plant-derived compound Resveratrol in brain cancer: A review. Biomolecules 2020, 10, 161. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Desai, V.; Bhushan, A. Natural bioactive compounds: Alternative approach to the treatment of glioblastoma multiforme. BioMed Res. Int. 2017, 2017. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Song, X.; Shu, X.-H.; Wu, M.-L.; Zheng, X.; Jia, B.; Kong, Q.-Y.; Liu, J.; Li, H. Postoperative resveratrol administration improves prognosis of rat orthotopic glioblastomas. BMC Cancer 2018, 18, 1–10. [Google Scholar] [CrossRef]
- Jiang, H.; Zhang, L.; Kuo, J.; Kuo, K.; Gautam, S.C.; Groc, L.; Rodriguez, A.I.; Koubi, D.; Hunter, T.J.; Corcoran, G.B.; et al. Resveratrol-induced apoptotic death in human U251 glioma cells. Mol. Cancer 2005, 4, 554–561. [Google Scholar] [CrossRef] [Green Version]
- Mawson, A.R. Retinoids in the treatment of glioma: A new perspective. Cancer Manag. Res. 2012, 4, 233. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Haar, C.P.; Hebbar, P.; Wallace, G.C.t.; Das, A.; Vandergrift, W.A., III; Smith, J.A.; Giglio, P.; Patel, S.J.; Ray, S.K.; Banik, N.L. Drug resistance in glioblastoma: A mini review. Neurochem. Res. 2012, 37, 1192–1200. [Google Scholar] [CrossRef]
- Lippman, S.M.; Lotan, R. Advances in the development of retinoids as chemopreventive agents. J. Nutr. 2000, 130, 479S–482S. [Google Scholar] [CrossRef] [PubMed]
- George, J.; Banik, N.L.; Ray, S.K. Survivin knockdown and concurrent 4-HPR treatment controlled human glioblastoma in vitro and in vivo. Neuro-Oncology 2010, 12, 1088–1101. [Google Scholar] [CrossRef] [Green Version]
- Chun, O.K.; Chung, S.J.; Song, W.O. Estimated dietary flavonoid intake and major food sources of US adults. J. Nutr. 2007, 137, 1244–1252. [Google Scholar] [CrossRef] [Green Version]
- Lesjak, M.; Beara, I.; Simin, N.; Pintać, D.; Majkić, T.; Bekvalac, K.; Orčić, D.; Mimica-Dukić, N. Antioxidant and anti-inflammatory activities of quercetin and its derivatives. J. Funct. Foods 2018, 40, 68–75. [Google Scholar] [CrossRef]
- Khan, F.; Niaz, K.; Maqbool, F.; Ismail Hassan, F.; Abdollahi, M.; Nagulapalli Venkata, K.C.; Nabavi, S.M.; Bishayee, A. Molecular targets underlying the anticancer effects of quercetin: An update. Nutrients 2016, 8, 529. [Google Scholar] [CrossRef]
- Pozsgai, E.; Bellyei, S.; Cseh, A.; Boronkai, A.; Racz, B.; Szabo, A.; Sumegi, B.; Hocsak, E. Quercetin increases the efficacy of glioblastoma treatment compared to standard chemoradiotherapy by the suppression of PI-3-kinase-Akt pathway. Nutr. Cancer 2013, 65, 1059–1066. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bose, S.; Banerjee, S.; Mondal, A.; Chakraborty, U.; Pumarol, J.; Croley, C.R.; Bishayee, A. Targeting the JAK/STAT Signaling Pathway Using Phytocompounds for Cancer Prevention and Therapy. Cells 2020, 9. [Google Scholar] [CrossRef] [PubMed]
- Atkinson, G.P.; Nozell, S.E.; Benveniste, E.T. NF-kappaB and STAT3 signaling in glioma: Targets for future therapies. Expert. Rev. Neurother. 2010, 10, 575–586. [Google Scholar] [CrossRef] [Green Version]
- Begley, D.J.; Brightman, M.W. Structural and functional aspects of the blood-brain barrier. Pept. Transp. Deliv. Into Cent. Nerv. Syst. 2003, 39–78. [Google Scholar]
- Pardridge, W.M. Brain Drug Targeting: The Future of Brain Drug Development; Cambridge University Press: Cambridge, UK, 2001. [Google Scholar]
- Woodworth, G.F.; Dunn, G.P.; Nance, E.A.; Hanes, J.; Brem, H. Emerging insights into barriers to effective brain tumor therapeutics. Front. Oncol. 2014, 4, 126. [Google Scholar] [CrossRef] [Green Version]
- Kim, S.-S.; Rait, A.; Rubab, F.; Rao, A.K.; Kiritsy, M.C.; Pirollo, K.F.; Wang, S.; Weiner, L.M.; Chang, E.H. The clinical potential of targeted nanomedicine: Delivering to cancer stem-like cells. Mol. Ther. 2014, 22, 278–291. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Allard, E.; Passirani, C.; Benoit, J.-P. Convection-enhanced delivery of nanocarriers for the treatment of brain tumors. Biomaterials 2009, 30, 2302–2318. [Google Scholar] [CrossRef] [PubMed]
- Zhu, J.; Wang, G.; Alves, C.S.; Tomás, H.; Xiong, Z.; Shen, M.; Rodrigues, J.O.; Shi, X. Multifunctional dendrimer-entrapped gold nanoparticles conjugated with doxorubicin for pH-responsive drug delivery and targeted computed tomography imaging. Langmuir 2018, 34, 12428–12435. [Google Scholar] [CrossRef] [PubMed]
- Hu, D.; Xu, H.; Xiao, B.; Li, D.; Zhou, Z.; Liu, X.; Tang, J.; Shen, Y. Albumin-stabilized metal–organic nanoparticles for effective delivery of metal complex anticancer drugs. ACS Appl. Mater. Interfaces 2018, 10, 34974–34982. [Google Scholar] [CrossRef]
- Hatcher, H.; Planalp, R.; Cho, J.; Torti, F.M.; Torti, S.V. Curcumin: From ancient medicine to current clinical trials. Cell Mol. Life Sci. 2008, 65, 1631–1652. [Google Scholar] [CrossRef]
- Dilnawaz, F.; Sahoo, S.K. Enhanced accumulation of curcumin and temozolomide loaded magnetic nanoparticles executes profound cytotoxic effect in glioblastoma spheroid model. Eur. J. Pharm. Biopharm. 2013, 85, 452–462. [Google Scholar] [CrossRef]
- Bhaskaran, M.; Devegowda, V.G.; Gupta, V.K.; Shivachar, A.; Bhosale, R.R.; Arunachalam, M.; Vaishnavi, T. Current Perspectives on Therapies, Including Drug Delivery Systems, for Managing Glioblastoma Multiforme. ACS Chem. Neurosci. 2020, 11, 2962–2977. [Google Scholar] [CrossRef]
- Miglierini, P.; Bouchekoua, M.; Rousseau, B.; Hieu, P.D.; Malhaire, J.P.; Pradier, O. Impact of the per-operatory application of GLIADEL wafers (BCNU, carmustine) in combination with temozolomide and radiotherapy in patients with glioblastoma multiforme: Efficacy and toxicity. Clin. Neurol. Neurosurg. 2012, 114, 1222–1225. [Google Scholar] [CrossRef] [PubMed]
- Weber, E.L.; Goebel, E.A. Cerebral edema associated with Gliadel wafers: Two case studies. Neuro. Oncol. 2005, 7, 84–89. [Google Scholar] [CrossRef]
- Miska, J.; Lesniak, M.S. Neural stem cell carriers for the treatment of glioblastoma multiforme. EBioMedicine 2015, 2, 774–775. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rampado, R.; Crotti, S.; Caliceti, P.; Pucciarelli, S.; Agostini, M. Recent advances in understanding the protein corona of nanoparticles and in the formulation of “Stealthy” Nanomaterials. Front. Bioeng. Biotechnol. 2020, 8, 166. [Google Scholar] [CrossRef] [PubMed]
- Xue, J.; Zhao, Z.; Zhang, L.; Xue, L.; Shen, S.; Wen, Y.; Wei, Z.; Wang, L.; Kong, L.; Sun, H. Neutrophil-mediated anticancer drug delivery for suppression of postoperative malignant glioma recurrence. Nat. Nanotechnol. 2017, 12, 692. [Google Scholar] [CrossRef]
- Cha, G.D.; Kang, T.; Baik, S.; Kim, D.; Choi, S.H.; Hyeon, T.; Kim, D.-H. Advances in drug delivery technology for the treatment of glioblastoma multiforme. J. Control. Release 2020, 328, 350–367. [Google Scholar] [CrossRef]
- Deng, Z.; Sheng, Z.; Yan, F. Ultrasound-induced blood-brain-barrier opening enhances anticancer efficacy in the treatment of glioblastoma: Current status and future prospects. J. Oncol. 2019. [Google Scholar] [CrossRef]
- Mukhtar, M.; Bilal, M.; Rahdar, A.; Barani, M.; Arshad, R.; Behl, T.; Brisc, C.; Banica, F.; Bungau, S. Nanomaterials for Diagnosis and Treatment of Brain Cancer: Recent Updates. Chemosensors 2020, 8. [Google Scholar] [CrossRef]
- Papachristodoulou, A.; Signorell, R.D.; Werner, B.; Brambilla, D.; Luciani, P.; Cavusoglu, M.; Grandjean, J.; Silginer, M.; Rudin, M.; Martin, E. Chemotherapy sensitization of glioblastoma by focused ultrasound-mediated delivery of therapeutic liposomes. J. Control. Release 2019, 295, 130–139. [Google Scholar] [CrossRef] [Green Version]
- Lesniak, W.G.; Chu, C.; Jablonska, A.; Du, Y.; Pomper, M.G.; Walczak, P.; Janowski, M. A distinct advantage to intraarterial delivery of 89Zr-bevacizumab in PET imaging of mice with and without osmotic opening of the blood–brain barrier. J. Nucl. Med. 2019, 60, 617–622. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Burgess, A.; Shah, K.; Hough, O.; Hynynen, K. Focused ultrasound-mediated drug delivery through the blood-brain barrier. Expert Rev. Neurother. 2015, 15, 477–491. [Google Scholar] [CrossRef] [Green Version]
- Harder, B.G.; Blomquist, M.R.; Wang, J.; Kim, A.J.; Woodworth, G.F.; Winkles, J.A.; Loftus, J.C.; Tran, N.L. Developments in Blood-Brain Barrier Penetrance and Drug Repurposing for Improved Treatment of Glioblastoma. Front. Oncol. 2018, 8, 462. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kim, D.G.; Kim, K.H.; Seo, Y.J.; Yang, H.; Marcusson, E.G.; Son, E.; Lee, K.; Sa, J.K.; Lee, H.W.; Nam, D.H. Anti-miR delivery strategies to bypass the blood-brain barrier in glioblastoma therapy. Oncotarget 2016, 7, 29400–29411. [Google Scholar] [CrossRef] [PubMed]
- Lammers, T.; Peschke, P.; Kühnlein, R.; Subr, V.; Ulbrich, K.; Huber, P.; Hennink, W.; Storm, G. Effect of intratumoral injection on the biodistribution and the therapeutic potential of HPMA copolymer-based drug delivery systems. Neoplasia 2006, 8, 788–795. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bastiancich, C.; Vanvarenberg, K.; Ucakar, B.; Pitorre, M.; Bastiat, G.; Lagarce, F.; Préat, V.; Danhier, F. Lauroyl-gemcitabine-loaded lipid nanocapsule hydrogel for the treatment of glioblastoma. J. Control. Release 2016, 225, 283–293. [Google Scholar] [CrossRef]
- Bastiancich, C.; Bianco, J.; Vanvarenberg, K.; Ucakar, B.; Joudiou, N.; Gallez, B.; Bastiat, G.; Lagarce, F.; Préat, V.; Danhier, F. Injectable nanomedicine hydrogel for local chemotherapy of glioblastoma after surgical resection. J. Control. Release 2017, 264, 45–54. [Google Scholar] [CrossRef]
- Chao, Y.; Liang, C.; Tao, H.; Du, Y.; Wu, D.; Dong, Z.; Jin, Q.; Chen, G.; Xu, J.; Xiao, Z. Localized cocktail chemoimmunotherapy after in situ gelation to trigger robust systemic antitumor immune responses. Sci. Adv. 2020, 6, eaaz4204. [Google Scholar] [CrossRef] [Green Version]
- Halin, C.; Niesner, U.; Villani, M.E.; Zardi, L.; Neri, D. Tumor-targeting properties of antibody–vascular endothelial growth factor fusion proteins. Int. J. Cancer 2002, 102, 109–116. [Google Scholar] [CrossRef]
- Lambert, J. Lambert JMDrug-conjugated monoclonal antibodies for the treatment of cancer. Curr Opin Pharmacol 5(5): 543–549. Curr. Opin. Pharmacol. 2005, 5, 543–549. [Google Scholar] [CrossRef] [PubMed]
- Schrama, D.; Reisfeld, R.A.; Becker, J.C. Antibody targeted drugs as cancer therapeutics. Nat. Rev. Drug Discov. 2006, 5, 147–159. [Google Scholar] [CrossRef]
- Thorpe, P.E.; Ran, S. Tumor infarction by targeting tissue factor to tumor vasculature. Cancer J. Sci. Am. 2000, 6, S237. [Google Scholar]
- Birchler, M.; Viti, F.; Zardi, L.; Spiess, B.; Neri, D. Selective targeting and photocoagulation of ocular angiogenesis mediated by a phage-derived human antibody fragment. Nat. Biotechnol. 1999, 17, 984–988. [Google Scholar] [CrossRef] [PubMed]
- Gerber, H.-P.; Senter, P.D.; Grewal, I.S. Antibody Drug-Conjugates Targeting the Tumor Vasculature: Current and Future Developments; Taylor & Francis: Abingdon, UK, 2009; pp. 247–253. [Google Scholar]
Compound Structure | Target Mechanism | Limitations | Ref. |
---|---|---|---|
Quercetin | ↑caspases 3 and 9 ↓survivin expression, antiapoptotic proteins ↓NFκB-associated PLD1 expression↓HSP27 ↓JAK/STAT3, MMP-2 secretion and cyclin D1 expression Inhibition of Bcl-xl, Bcl-2 and cytochrome c. | Clarification of the mechanism of action as a single therapy or in combination with standard chemotherapeutic therapies is still needed. | [129,130,131,132,133,134,135,136,137,138,139,140,141] |
Chrysin | ↓ErK/Nrf2 pathway ↓Nrf2, NADPH quinine oxidoreductase-1 and heme oxygenase-1 ↑glutathione peroxidase, superoxide dismutase and catalase activity modulation of MAPK/ERK and P38 induction of caspase-3 and 8. | Chrysin has reduced bioavailability due to its acute metabolism, novel dosage forms, like nanoparticles micelles and liposomes as carriers are needed to increase its bioavailability. | [142,143,144,145,146,147,148,149,150,151] |
Luteolin | ↓iNOS expression ↑miR-7-1-3p, ↓PKCα ↓IL-1β, p65, NF-κB, c-Jun amino-terminal kinase ↓p-AKT ↑caspases 3 and 8. | Clarification of the mechanism of action and clinical research is still needed. | [152,153,154,155,156,157,158,159] |
Genistein | ↓tyrosine kinase mediated signaling ↑p53 and p21 ↓cyclin B and cyclin D1 and TERT ↑caspase-3,9. | Clinical trial studies during the different stages of GBM are needed. Mechanism of action is needed to be explored. | [160,161,162,163,164,165,166,167,168,169] |
Catechins | ↓MAPK ↓TNFα and NO ↓NF-κB ↑caspase-8. | Studies are needed to define its use in clinical treatment. | [170,171,172,173,174,175,176,177,178] |
Resveratrol | Regulates isocitrate dehydrogenases regulation of STAT3 pathway ↓survivin and antiapoptotic proteins ↓NF-κB signaling ↑caspase 3. | Improvement in solubility, efficient and effective intravenous delivery, first-pass metabolism reduction and enhancement of bioavailability are needed to be studied. | [179,180,181,182,183] |
Retinoids | Regulates cyclin D and cyclin D1 proteins, mediates intracellular and extracellular signaling proteins like, ICAM1, cadherin 6, FLRT1 ITGB3. | Details of the molecular mechanism and clinical trial data are needed. | [178,184,185,186,187] |
Delivery Systems | Characteristics | Advantages for the Treatment of GBM | Ref. |
---|---|---|---|
Nanoparticles | They are made up of biodegradable polymers conjugated to drugs and antibodies to recognize cancer cells. | Can penetrate even into small vessels, while the larger size of nanoparticles develops immunogenicity and encourages their release through the reticular endothelial pathway (thus favoring targeted delivery to cancer cells). | [194,195,196,197,198,199,200,201,202,203] |
Gliadel wafers | A biodegradable polymer of carmustine (1,3-bis [2-chloroethyl]-1-nitrosourea [BCNU]), supplying a controlled release gradually for 2–3 weeks period. | Improved drug delivery, reduced systemic adverse effects in recurrent glioma treatment. | [204,205] |
Drug Delivery in Brain Tissue using Cellular Carriers | Cell-mediated targeted delivery through erythrocytes, leukocytes, platelets and stem cells. | Effectively penetrate deeper into the tumor, tumor recurrence was very slow, improved survival rate. | [206,207,208,209] |
BBB transient disruption for enhanced drug delivery | Disrupting the integrity of BBB with low-intensity focused ultrasound (LIFU). | Increase the bioavailability and therapeutic efficacy of drugs. | [212,213,214] |
Intra tumoral injection of drug-loaded vehicles | They are made up of polymer alginate with calcium ions, forming hydrogel within the tissue site. | Enhanced therapeutic potential and reduced systemic toxicity. | [219,220] |
Vascular targeting via antibodies | Antibody is conjugated to a cytotoxic drug through a linker. | Damage of the tumor neovasculature causes massive death of tumor cells. | [221] |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Behl, T.; Sharma, A.; Sharma, L.; Sehgal, A.; Singh, S.; Sharma, N.; Zengin, G.; Bungau, S.; Toma, M.M.; Gitea, D.; et al. Current Perspective on the Natural Compounds and Drug Delivery Techniques in Glioblastoma Multiforme. Cancers 2021, 13, 2765. https://doi.org/10.3390/cancers13112765
Behl T, Sharma A, Sharma L, Sehgal A, Singh S, Sharma N, Zengin G, Bungau S, Toma MM, Gitea D, et al. Current Perspective on the Natural Compounds and Drug Delivery Techniques in Glioblastoma Multiforme. Cancers. 2021; 13(11):2765. https://doi.org/10.3390/cancers13112765
Chicago/Turabian StyleBehl, Tapan, Aditi Sharma, Lalit Sharma, Aayush Sehgal, Sukhbir Singh, Neelam Sharma, Gokhan Zengin, Simona Bungau, Mirela Marioara Toma, Daniela Gitea, and et al. 2021. "Current Perspective on the Natural Compounds and Drug Delivery Techniques in Glioblastoma Multiforme" Cancers 13, no. 11: 2765. https://doi.org/10.3390/cancers13112765
APA StyleBehl, T., Sharma, A., Sharma, L., Sehgal, A., Singh, S., Sharma, N., Zengin, G., Bungau, S., Toma, M. M., Gitea, D., Babes, E. E., Judea Pusta, C. T., & Bumbu, A. G. (2021). Current Perspective on the Natural Compounds and Drug Delivery Techniques in Glioblastoma Multiforme. Cancers, 13(11), 2765. https://doi.org/10.3390/cancers13112765